Injecting risk behaviours among people who inject drugs (PWID) and high-risk sexual practices among men who have sex with men (MSM) are important routes of hepatitis C virus (HCV) transmission. Current direct-acting antiviral treatment offers unique opportunities for reductions in HCV-related liver disease burden and epidemic control in high-risk groups, but these prospects could be counteracted by HCV reinfection due to on-going risk behaviours after successful treatment. Based on existing data from small and heterogeneous studies of interferon-based treatment, the incidence of reinfection after sustained virological response range from 2–6/100 person years among PWID to 10–15/100 person years among human immunodeficiency virus-infected MSM. These differences mainly reflect heterogeneity in study populations with regards to risk behaviours, but also reflect variations in study designs and applied virological methods.
|Number of pages||13|
|Journal||Journal of Hepatology|
|Issue number||1 (Supplement)|
|Early online date||30 Sep 2016|
|Publication status||Published - Oct 2016|
- hepatitis C
Midgard, H., Weir, A., Palmateer, N., Lo Re III, V., Pineda, J. A., Macias, J., & Dalgard, O. (2016). HCV epidemiology in high-risk groups and the risk of reinfection. Journal of Hepatology, 65(1 (Supplement) ), S33–S45. https://doi.org/10.1016/j.jhep.2016.07.012